[go: up one dir, main page]

NO990436D0 - FremgangsmÕte for behandling av bipolar forstyrrelse - Google Patents

FremgangsmÕte for behandling av bipolar forstyrrelse

Info

Publication number
NO990436D0
NO990436D0 NO990436A NO990436A NO990436D0 NO 990436 D0 NO990436 D0 NO 990436D0 NO 990436 A NO990436 A NO 990436A NO 990436 A NO990436 A NO 990436A NO 990436 D0 NO990436 D0 NO 990436D0
Authority
NO
Norway
Prior art keywords
bipolar disorder
procedure
treatment
humans
chem
Prior art date
Application number
NO990436A
Other languages
English (en)
Other versions
NO990436L (no
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO990436L publication Critical patent/NO990436L/no
Publication of NO990436D0 publication Critical patent/NO990436D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Press Drives And Press Lines (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
NO990436A 1996-08-01 1999-01-29 FremgangsmÕte for behandling av bipolar forstyrrelse NO990436D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2290096P 1996-08-01 1996-08-01
PCT/US1997/013185 WO1998005324A1 (en) 1996-08-01 1997-07-28 Method for treating bipolar disorder

Publications (2)

Publication Number Publication Date
NO990436L NO990436L (no) 1999-01-29
NO990436D0 true NO990436D0 (no) 1999-01-29

Family

ID=21812011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990436A NO990436D0 (no) 1996-08-01 1999-01-29 FremgangsmÕte for behandling av bipolar forstyrrelse

Country Status (19)

Country Link
EP (1) EP0821955B1 (no)
JP (1) JP2000515547A (no)
KR (1) KR20000029647A (no)
CN (1) CN1226165A (no)
AT (1) ATE213413T1 (no)
AU (1) AU716972B2 (no)
BR (1) BR9710901A (no)
CA (1) CA2261802C (no)
CZ (1) CZ27299A3 (no)
DE (1) DE69710526T2 (no)
DK (1) DK0821955T3 (no)
EA (1) EA199900174A1 (no)
ES (1) ES2171838T3 (no)
HU (1) HUP9904578A2 (no)
IL (1) IL128280A0 (no)
NO (1) NO990436D0 (no)
PL (1) PL331407A1 (no)
PT (1) PT821955E (no)
WO (1) WO1998005324A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3646870A1 (en) * 2009-07-22 2020-05-06 Puretech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
CN111430027B (zh) * 2020-03-18 2023-04-28 浙江大学 基于肠道微生物的双相情感障碍生物标志物及其筛选应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
WO1995005174A1 (en) * 1993-08-19 1995-02-23 Novo Nordisk A/S Antipsychotic method
US5646289A (en) * 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use
DE69516076T2 (de) * 1994-10-31 2000-09-14 Eli Lilly And Co., Indianapolis Tetrahydropyridin Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety

Also Published As

Publication number Publication date
EP0821955A2 (en) 1998-02-04
HUP9904578A2 (hu) 2000-06-28
ES2171838T3 (es) 2002-09-16
EP0821955A3 (en) 1998-04-22
AU4046897A (en) 1998-02-25
CA2261802C (en) 2006-11-07
CN1226165A (zh) 1999-08-18
PL331407A1 (en) 1999-07-19
ATE213413T1 (de) 2002-03-15
CZ27299A3 (cs) 1999-08-11
PT821955E (pt) 2002-07-31
JP2000515547A (ja) 2000-11-21
NO990436L (no) 1999-01-29
WO1998005324A1 (en) 1998-02-12
EA199900174A1 (ru) 1999-08-26
DE69710526D1 (de) 2002-03-28
IL128280A0 (en) 1999-11-30
KR20000029647A (ko) 2000-05-25
DK0821955T3 (da) 2002-03-18
DE69710526T2 (de) 2002-10-02
AU716972B2 (en) 2000-03-09
EP0821955B1 (en) 2002-02-20
BR9710901A (pt) 1999-08-17
CA2261802A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
ATE152111T1 (de) K-252a derivate
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
DK0627221T3 (da) Substans P antagonister til behandling af emesis
DE69331171D1 (de) Chinolin und Chinazolin Derivate zur Behandlung von Arthritis
ATE122232T1 (de) Melatoninderivate und kombinationen mit antiestrogenen zur behandlung von brustkarzinoma.
ATE156359T1 (de) Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
NO990436D0 (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
NO990450D0 (no) Behandling av sinnslidelser
NO20003481L (no) FremgangsmÕte for behandling av COPD
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
DE69706195D1 (de) Antikonvulsive derivate zur behandlung von psoriasis
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
ATE61585T1 (de) N-carboxyalcoyl-2-oxo-3-diaryl-5-6 triazine als heilmittel.
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler